Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 7,439 matching trials from the live ClinicalTrials.gov search.

Filters: Aurora, Colorado Clear all

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Prostate Cancer
Interventions: Decipher; Other
Lead sponsor: GenomeDx Biosciences Corp; Industry
Eligibility: Male only
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 19
States / cities: Anchorage, Alaska • Los Angeles, California • Aurora, Colorado + 15 more

Conditions: Levels of Pain
Interventions: Epic 10 Diode Laser by Biolase Inc., Placebo; Device · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Years to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: COPD, Heart Failure, Cancer
Interventions: Storytelling Intervention for Patient Participants, Storytelling Intervention for Nurse Participants; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Menopausal and Female Climacteric States
Interventions: Other: Placebo, GSK232802, PREMARIN; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 41
States / cities: Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 35 more

Conditions: Carcinoma, Renal Cell
Interventions: Belzutifan, Everolimus; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 29
States / cities: Birmingham, Alabama • La Jolla, California • Santa Rosa, California + 23 more

Conditions: Stroke, Secondary Prevention
Interventions: optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 5,390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 110
States / cities: Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more

Conditions: Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions: S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 21
States / cities: Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy; Drug · Procedure · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 361
States / cities: Mobile, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 264 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: CAPTURE Tool; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 45 Years to 80 Years
Enrollment: 4,679 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 4 more

Conditions: Mental Disorder, Child, Mental Health, Family Health
Interventions: Parent Peer Navigation; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 1 Year to 99 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Aurora, Colorado • Salem, Oregon • Pittsburgh, Pennsylvania + 1 more

Conditions: Peanut Allergy
Interventions: Viaskin Peanut 250 µg, Placebo; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 26
States / cities: Little Rock, Arkansas • Mission Viejo, California • Rolling Hills Estates, California + 21 more

Conditions: Respiratory Syncytial Virus Infection
Interventions: Clesrovimab, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: Up to 1 Year
Enrollment: 3,632 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 51
States / cities: Dothan, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 45 more

Conditions: Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: New York Medical College; Other
Eligibility: 1 Day to 21 Years
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2031
U.S. locations: 13
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Non-Arteritic Anterior Ischemic Optic Neuropathy
Interventions: Cenegermin, Vehicle; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 27
States / cities: Los Angeles, California • Newport Beach, California • Palo Alto, California + 21 more

Conditions: Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions: BMN 110; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: Not listed
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more

Conditions: Colonic Neoplasms
Interventions: Not listed
Lead sponsor: Metabiomics Corp; Industry
Eligibility: 18 Years to 95 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Mesothelin-expressing Advanced Cancers
Interventions: ZW171; Drug
Lead sponsor: Zymeworks BC Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 4 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Nelfinavir mesylate, Efavirenz; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 49
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 32 more

Conditions: Cardiovascular Disease, Acute Coronary Syndrome
Interventions: Multifaceted Intervention with pharmacist and IVR; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 91 Years
Enrollment: 14,573 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 15
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 12 more

Conditions: Cannabis Use Disorder
Interventions: Dronabinol Pill, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 40 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Focal Epilepsy
Interventions: XEN1101; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 54
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more

Conditions: Ulcerative Colitis
Interventions: Etrasimod, Placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 62
States / cities: Dothan, Alabama • Mobile, Alabama • Sun City, Arizona + 54 more

Conditions: Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Rucaparib; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 950
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more

Search by objective public record fields.

Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

Effect of Low Level Laser Therapy on Pain Induced by Placement of Orthodontic Separators in Pediatric Patients

Personalized Experiences to Inform Improved Communication for Minorities With Life Limiting Illness

Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 1)

Navigation and Parent Peer Support to Promote Access

Safety Study of Viaskin Peanut to Treat Peanut Allergy

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

BMN 110 US Expanded Access Program

Metabiomics Colon Cancer Clinical Research Study

A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers

Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen

Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence

Effects of THC on Alcohol Consumption and Neural Correlates of Reward

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)